An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally-Administered SGLT2 Inhibitor TA-7284

The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes.

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes Mellitus
• Intervention / Treatment: Drug: Placebo; Drug: TA-7284-Low; Drug: TA-7284-Low-middle; Drug: TA-7284-High-middle; Drug: TA-7284-High

Detailed Description

Type 2 diabetes mellitus (T2DM) is well recognized as a major public health problem that presents patients with a significant risk of complications including heart disease, retinopathy, nephropathy, and neuropathy. Various classes of orally administered antihyperglycemic agents have been developed for the treatment of T2DM and although individual agents may be highly effective for some patients, it is still difficult to maintain optimal glycemic control in most patients, resulting in high rates of morbidity and mortality in the diabetic population. This is a randomized, double-blind, placebo-controlled, parallel-group study to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with T2DM, who are not optimally controlled on diet and exercise. The primary study hypothesis is that the study drug will be superior to placebo as assessed by the change in HbA1c from baseline. The patients will receive tablets of TA-7284, or placebo, once daily for 12 weeks.

• Study Type: Interventional
• Enrollment (Actual): 383
• Phase: Phase 2

Contacts and Locations

Study Locations

• Japan
  • Chugoku, Japan
    • Research Site
  • Kanto, Japan
    • Research Site
  • Kinki, Japan
    • Research Site
  • Kyushu, Japan
    • Research Site
  • Shikoku, Japan
    • Research Site
  • Tōhoku, Japan
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Aged from 20 to 80 years inclusive on the day of informed consent;
• Patients who was diagnosed with type 2 diabetes mellitus at least 3 months before the start of the run-in period;
• Patients with HbA1c of ≥6.5% and ≤9.5% (according to the Japan Diabetic Society [JDS] criteria) on the start day of the run-in period;

Exclusion Criteria:

• Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (acromegaly, Cushing's syndrome, etc.);
• Past or current history of severe diabetic complications (proliferative diabetic retinopathy, stage III or later stage overt nephropathy, diabetic ketoacidosis, or serious diabetic neuropathy);
• Fasting blood glucose of >270 mg/dL on the start day of the run-in period or at Week 2 of the run-in period;
• eGFR of <60 mL/min/1.73 m2 on the start day of the run-in period;
• Systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg on the start or end day of the run-in period;
• History of myocardial infarction, unstable angina, or cerebrovascular disorder within 3 months before the start of the run-in period;
• Concurrent serious (e.g., requiring inpatient hospitalization or surgical intervention) renal or hepatic disease;
• Past or current history of malignant tumor; however, this criterion shall not apply to those who have been free of relapse for at least 5 years even with a history of malignant tumor.
• Past or current history of drug hypersensitivity such as shock and anaphylactoid symptoms;
• Pregnant women, lactating mothers, or women of childbearing potential;
• Any condition that subjects are assessed to be ineligible by the investigator (sub investigator).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Placebo
Experimental: TA-7284-Low	Drug: TA-7284-Low; TA-7284-Low
Experimental: TA-7284-Low-middle	Drug: TA-7284-Low-middle; TA-7284-Low-middle
Experimental: TA-7284-High-middle	Drug: TA-7284-High-middle; TA-7284-High-middle
Experimental: TA-7284-High	Drug: TA-7284-High; TA-7284-High

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value)	12 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Fasting Blood Glucose, Body Weight	12 weeks
Safety and Tolerability	14 weeks

Collaborators and Investigators

• Sponsor: Tanabe Pharma Corporation
• Investigators: Study Director: Nobuya Inagaki, M.D., Kyoto University, Graduate School of Medicine; Study Director: Kazuoki Kondo, M.D., Tanabe Pharma Corporation; Study Director: Tadashi Yoshida, M.D., Tanabe Pharma Corporation

Study record dates

Study Major Dates

• Study Start: November 1, 2009
• Primary Completion (Actual): September 1, 2010
• Study Completion (Actual): September 1, 2010

Study Registration Dates

• First Submitted: November 29, 2009
• First Submitted That Met QC Criteria: November 29, 2009
• First Posted (Estimated): December 1, 2009

Study Record Updates

• Last Update Posted (Estimated): January 8, 2026
• Last Update Submitted That Met QC Criteria: December 15, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Type 2 diabetes mellitus; Canagliflozin; JNJ-28431754; TA-7284; Sodium Glucose Co-transporter (SGLT2 inhibitor)
• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 2
• Other Study ID Numbers: TA-7284-04